MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

At ACC 2025, new real-world safety data were presented on sotatercept, a novel fusion protein for pulmonary arterial ...

Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0 ...

XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...

The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or ...

X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

Called neutrophilia, high neutrophils can mean you have an acute infection or injury. Low neutrophils, called neutropenia, may be caused by chronic infections or autoimmune conditions. In rare cases, ...

However, chemotherapy often induces neutropenia (chemotherapy-induced neutropenia, CIN), increasing the risk of infectious complications and mortality. Current research suggests that gut microbiota ...

Marked neutropenia can be the initial abnormal laboratory finding in patients with XLA who are presenting with their first illness. The two cases presented herein support early consideration of ...